GSK (LSE:GSK) shares gained 2.26% on Friday, rising in sympathy with a sector peer on a day when most of the market was looking for shelter from a technology sell-off. There was no company-specific announcement identified for the session. The move is best read as a pharma sector reaction to AstraZeneca's results rather than as news about GSK itself.

GSK is one of Britain's largest drugmakers, with a Business built around prescription medicines and vaccines. Companies of this type are often treated as defensive holdings because Demand for medicines is less sensitive to the economic cycle than demand for many other goods and services. That reputation tends to draw attention when investors are nervous about growth stocks, and Friday was such a day. Nothing in the available reporting pointed to a trading update, regulatory decision, broker note or corporate action at GSK. The stated reason for the rise was simply that the pharma peer rose alongside AstraZeneca's surge.

AstraZeneca (LSE:AZN) was the clear catalyst for the group. It jumped 7%, its best day in a year, after third-quarter results and a savings plan of about $1.5bn. Good numbers from one of the sector's biggest names can lift sentiment towards the others, particularly when the market is searching for areas that look stable. GSK's gain was a third of AstraZeneca's size, which is consistent with a sympathy move rather than a re-rating on its own news.

The wider market gave plenty of reasons to seek out safer ground. The FTSE 100 closed up 7.71 points, or 0.07%, at 10,729.78, after drifting in and out of positive territory and finishing well off its intraday highs. Large-cap defensives held the Blue-Chip index up while a US tech sell-off pushed it down. On Wall Street, the S&P 500 fell 1.82% to 7,580.07, the Dow Jones Industrial Average lost 1.09% to 51,770.31, and the Nasdaq Composite dropped 2.86% to 25,437.00. It was Wall Street's worst day since June.

The cause was weak results from Intel and Amazon, released after Thursday's close, which revived doubts that heavy spending on artificial intelligence will pay off. Intel fell about 30% in New York, a chip index dropped 7.2%, and Alphabet had already tumbled 12% on Thursday over the same concerns. In London, Computacenter (LSE:CCC), Polar Capital Technology (LSE:PCT) and Scottish Mortgage (LSE:SMT) all fell as the Nasdaq dropped about 2.7% at the London close.

Consumer staples were the other pocket of strength. Diageo (LSE:DGE), CCEP (LSE:CCEP), Unilever (LSE:ULVR), BAT (LSE:BATS), Reckitt (LSE:RKT), Sainsbury (LSE:SBRY) and Tesco (LSE:TSCO) all gained, and BT (LSE:BT.A) rose 6.7% on a press report that Virgin Media O2 is nearing a deal to use Openreach. Banks went the other way: NatWest (LSE:NWG) fell about 8.8% after disappointing net interest Margin guidance, dragging on Lloyds (LSE:LLOY) and Barclays (LSE:BARC). Miners also slipped as gold dropped about 2.8% to around $3,898 an ounce and copper declined.

Elsewhere, Brent Crude rose to about $117.61 a barrel, sterling briefly topped EUR1.20 for the first time since April 2025, and UK house price data showed the slowest October growth since 2024. Smaller companies fared worse than the blue chips, with the FTSE 250 down 0.9% to 24,453.36 and the AIM All-Share down 1.4%.

For GSK (LSE:GSK), then, the picture is one of a stock moving with its sector on a defensive day. There was no Earnings release or product news behind the rise, and the reporting did not offer any GSK-specific explanation. Whether the sympathy move with AstraZeneca carries any further is not something the day's facts can answer.

The month ended on a positive note for the index. The FTSE 100 rose just over 1% in October, its first monthly gain in three months, and about 0.37% on the week. Friday's session was the last of October, and it closed with the blue-chip index barely higher.